After Pfizer and Serum Institute of India, Bharat Biotech has become the third pharma major to seek a nod from Drug Controller General of India (DCGI) for emergency use authorisation for its COVID-19 vaccine, Covaxin.
Sources told CNBC-TV18 that Bharat Biotech has filed an application with the DCGI seeking emergency use authorisation for Covaxin.
Pfizer and Serum Institute sought emergency use authorisation on December 5 and 6, respectively. Sources said that an internal review of the applications had commenced under the accelerated review process, which is likely to conclude within two weeks.
"The Drug Controller General of India is likely to look into these applications under the accelerated review process for granting emergency use authorisation, and an outcome is expected over the next two weeks," sources said.
First Published: IST